Chelating Compound Imaging Method Reducing Background Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging methods for cancer, particularly those using folate-targeted agents, face challenges in reducing background organ activity and achieving high tumor-to-background ratios, which affects the accuracy and effectiveness of cancer imaging.
Innovation Solution
The method involves administering an unlabeled chelating compound and a labeled chelating compound, specifically a radionuclide-labeled etarfolatide, to patients to enhance the uptake of the labeled compound by cancer cells while minimizing background activity, using a folate receptor-mediated approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If folate-targeted imaging agents are administered to image cancer cells, then tumor detection capability is improved, but background organ activity increases which reduces imaging accuracy
Solution Approach 1:
The patent applies preliminary anti-action by administering an unlabeled chelating compound before the labeled imaging agent. This unlabeled compound pre-occupies the folate receptors in normal tissues, preventing the labeled agent from binding to these receptors and creating background signal. The sequence is critical: unlabeled first, then labeled, which blocks background uptake while allowing tumor detection.
Solution Approach 2:
The unlabeled chelating compound is administered in advance to prepare the biological system for subsequent imaging. It performs the preliminary action of saturating non-target folate receptors, thereby clearing the path for the labeled agent to selectively accumulate only in tumor tissues with high folate receptor expression, improving the tumor-to-background ratio.
2Measurement precision
If unlabeled chelating compound is administered before labeled compound, then tumor-to-background ratio is improved, but treatment complexity increases
Solution Approach 1:
The patent uses compounds with identical chemical structures that differ only by the presence or absence of a radionuclide label. Both the unlabeled and labeled compounds share the same folate-targeting moiety and chelating structure, allowing them to interact with the same biological targets. This universality simplifies the methodology despite the two-step administration protocol.
Solution Approach 2:
The invention changes the radioactivity parameter of the chelating compound to create two versions: one unlabeled (for pre-treatment) and one labeled (for imaging). This parameter change allows the same molecular entity to serve dual purposes: blocking background signal when unlabeled and providing detectable signal when labeled, thereby managing complexity through a single molecular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the tumor-to-background ratio, allowing for more accurate and effective imaging of cancers by reducing non-specific uptake in normal tissues and increasing the visibility of folate receptor-expressing tumors.
Implementation Method 1
the folate receptor, via receptor mediated endocytosis, is capable of internalizing folate conjugates
Implementation Method 2
M is a cation of a radionuclide
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present disclosure relates to a method for imaging cancer by administering to a patient a labeled chelating compound and an unlabeled chelating compound.